Pharmaceutical CDMO Recipharm announced on Monday that its subsidiary ReciBioPharm has secured a three-year grant from the Bill & Melinda Gates Foundation to support the global deployment of its xRNA Continuous Manufacturing platform.

The funding will focus on enhancing inline Process Analytical Technologies (PAT) and predictive analytics software for Low- and Middle-Income Countries (LMICs). This initiative aims to improve the scalability, quality and accessibility of RNA-based therapeutics.

ReciBioPharm's platform is designed to advance the development of fully integrated, continuous processes within biomanufacturing. The project builds on innovations from an MIT initiative funded by the FDA. ReciBioPharm is committed to leveraging these technologies to address global health challenges. This grant reinforces the company's role in expanding access to critical RNA solutions worldwide.